Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

BACKGROUND. Octreotide LAR is used in patients for control of carcinoid syndrome (CS) and other symptoms of hormone hypersecretion. The aim of this study was to examine reasons for octreotide LAR dose escalation and observe CS symptom improvement in patients with neuroendocrine tumors (NETs) who und...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Strosberg, Jonathan R., Benson, Al B., Huynh, Lynn, Duh, Mei Sheng, Goldman, Jamie, Sahai, Vaibhav, Rademaker, Alfred W., Kulke, Matthew H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2014
Konular:
Gastrointestinal Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4153451/
https://ncbi.nlm.nih.gov/pubmed/25096997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0120
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller